Claritas Pharmaceuticals Stock Net Income
| CLAZF Stock | USD 0.0001 0.00 0.00% |
Fundamental analysis of Claritas Pharmaceuticals allows traders to better anticipate movements in Claritas Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Claritas |
Claritas Pharmaceuticals Company Net Income Analysis
Claritas Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Claritas Pharmaceuticals Net Income | 4.21 M |
Most of Claritas Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Claritas Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Claritas Pharmaceuticals reported net income of 4.21 M. This is 98.77% lower than that of the Healthcare sector and 93.99% lower than that of the Biotechnology industry. The net income for all United States stocks is 99.26% higher than that of the company.
Claritas Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Claritas Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Claritas Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Claritas Pharmaceuticals by comparing valuation metrics of similar companies.Claritas Pharmaceuticals is currently under evaluation in net income category among its peers.
Claritas Fundamentals
| Return On Equity | 0.65 | |||
| Return On Asset | 0.0277 | |||
| Current Valuation | 948.45 K | |||
| Shares Outstanding | 36.59 M | |||
| Shares Owned By Insiders | 0.26 % | |||
| Price To Earning | 0.04 X | |||
| Price To Book | 0.12 X | |||
| EBITDA | (449 K) | |||
| Net Income | 4.21 M | |||
| Cash And Equivalents | 2 K | |||
| Total Debt | 538 K | |||
| Debt To Equity | 0.16 % | |||
| Current Ratio | 1.42 X | |||
| Book Value Per Share | 0.09 X | |||
| Cash Flow From Operations | (309 K) | |||
| Earnings Per Share | 0.15 X | |||
| Beta | 2.25 | |||
| Market Capitalization | 664.66 K | |||
| Total Asset | 10.45 M | |||
| Z Score | 0.6 | |||
| Net Asset | 10.45 M |
About Claritas Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Claritas Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Claritas Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Claritas Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Claritas Pink Sheet
Claritas Pharmaceuticals financial ratios help investors to determine whether Claritas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Claritas with respect to the benefits of owning Claritas Pharmaceuticals security.